On the other hand, 36 subjects out of the 80 not requiring treatment at the first visit (45 percent) had a lymphocyte count ^30 percent; the difference in the mean proportion of high-intensity alveolitis between these two groups was not significant (p=0.087). antibiotics levaquin
To evaluate the prognostic value of the initial BAL lymphocyte count, we excluded the 20 patients who were treated before six months of follow-up. Of the remaining patients, the 44 subjects with a high-intensity alveolitis (2:30 percent lymphocytes) at diagnosis were compared with the 34 with a lower BAL lymphocyte count (<30 percent). Pulmonary function test results obtained at their last follow-up visit or before treatment were used as the evaluation criteria. In both groups, the mean duration of follow-up was 23.1 months. To ensure the comparability of the mean pulmonary function measurements in the two groups, all the analyses were adjusted for the duration of follow-up and for the pulmonary function values at the time of diagnosis. Pulmonary function values were not different for subjects with high- or low^intensity alveolitis at diagnosis (Fig 1, A). Similar results were obtained when only subjects with biopsy-proven sarcoidosis were analyzed (Fig 1, B). Further analysis grouping subjects into three categories according to their percentage lymphocyte count (<30, 30 to 39, ^40 percent) instead of two showed no trend in any of these parameters (data not shown).
Figure 1. Mean pulmonary (unction measured at the end of follow-up for patients who had a follow-up of at least six months without treatment. A, All patients. B, Patients with biopsy-proven sarcoidosis. Subjects were grouped according to the BAL lymphocyte count at diagnosis (<30 percent, solid bars; ^30 percent, hatched bars). The means (SEM) are adjusted for the pulmonary function values obtained at diagnosis and the follow-up duration. No significant difference could be seen in these parameters between the subgroups of patients.